.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Department of Justice
Cerilliant
Express Scripts
McKesson
Chubb
Moodys
Boehringer Ingelheim
Harvard Business School
Accenture

Generated: July 24, 2017

DrugPatentWatch Database Preview

Acorda Company Profile

« Back to Dashboard

What is the competitive landscape for ACORDA, and what generic alternatives to ACORDA drugs are available?

ACORDA has four approved drugs.

There are six US patents protecting ACORDA drugs.

There are fifty-eight patent family members on ACORDA drugs in twenty-three countries.

Summary for Applicant: Acorda

Patents:6
Tradenames:3
Ingredients:3
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe► Subscribe
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010ABRXYesYes► Subscribe► Subscribe ► Subscribe
Acorda
ZANAFLEX
tizanidine hydrochloride
CAPSULE;ORAL021447-001Aug 29, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe
Acorda
ZANAFLEX
tizanidine hydrochloride
CAPSULE;ORAL021447-003Aug 29, 2002ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Acorda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acorda
AMPYRA
dalfampridine
TABLET, EXTENDED RELEASE;ORAL022250-001Jan 22, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ACORDA drugs

Drugname Dosage Strength Tradename Submissiondate
dalfampridine
Extended-release Tablets10 mg
AMPYRA
1/22/2014
tizanidine hydrochloride
Capsules2 mg, 4 mg and 6 mg
ZANAFLEX
8/10/2007

Non-Orange Book Patents for Acorda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,370,879 Formulations and their use in the treatment of neurological diseases► Subscribe
6,248,788 Therapeutic method with capsaicin and capasicin analogs► Subscribe
5,580,580 Formulations and their use in the treatment of neurological diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Acorda Drugs

Country Document Number Estimated Expiration
European Patent Office2460521► Subscribe
European Patent Office2460521► Subscribe
New Zealand240439► Subscribe
European Patent Office2377536► Subscribe
Spain2367707► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Acorda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0612Netherlands► SubscribePRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
C/GB11/055United Kingdom► SubscribePRODUCT NAME: 4-AMINOPYRIDINE OR A SALT THEREOF; REGISTERED: UK EU/1/11/699/001 20110720; UK EU/1/11/699/002 20110720
2012001Lithuania► SubscribePRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720
90033-9Sweden► SubscribePRODUCT NAME: 4-AMINOPYRIDIN ELLER ETT SALT DAERAV; REG. NO/DATE: EU/1/11/699/001 20110720
2013000046Germany► SubscribePRODUCT NAME: 4-AMINOPYRIDIN ODER EIN DERIVAT DAVON, INSBESONDERE EIN SALZ, EIN SOLVAT ODER EINE PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Julphar
Merck
QuintilesIMS
Deloitte
Chinese Patent Office
Cantor Fitzgerald
Cipla
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot